Reduced-intenstity hematopoietic cell transplantation for higher-risk MDS in elderly patients

Allogeneic hematopoietic cell transplantation is the only potentially curative therapy for MDS, although it is infrequently offered to elderly patients. A multicenter biologic assignment trial of reduced-intensity alloHCT based on donor availibility evaluated alloHCT for advanced myelodysplastic syndrome in patients aged 50 tot 75 years (median 66.7 years). OS and LFS were superior in the Donor arm compared with the No-Donor arm. The authors conclude that alloHCT should be included as an integral part of MDS management plans in fit older adults with higher-risk MDS.